Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 21

1.

The Ca2+ export pump PMCA clears near-membrane Ca2+ to facilitate store-operated Ca2+ entry and NFAT activation.

Go CK, Hooper R, Aronson MR, Schultz B, Cangoz T, Nemani N, Zhang Y, Madesh M, Soboloff J.

Sci Signal. 2019 Oct 8;12(602). pii: eaaw2627. doi: 10.1126/scisignal.aaw2627.

PMID:
31594854
2.

Prolapse of Aortic Right Coronary Cusp Causing Right Ventricular Outflow Tract Obstruction in a Child With Large Ventricular Septal Defect.

Joshi A, Babu S, Nemani N, Kiran M, Ramanan S, Koshy T.

A A Pract. 2019 Oct 1;13(7):284-286. doi: 10.1213/XAA.0000000000001054. No abstract available.

PMID:
31283533
3.

Diagnosis of an Additional Ventricular Septal Defect by Observing Dark Blood in Aortic Root Vent: A Case Report.

Babu S, Gadhinglajkar S, Sreedhar R, Nemani N, Sukesan S, Baruah SD.

A A Pract. 2019 Jul 15;13(2):61-64. doi: 10.1213/XAA.0000000000000991.

PMID:
30985324
4.

Blockade of MCU-Mediated Ca2+ Uptake Perturbs Lipid Metabolism via PP4-Dependent AMPK Dephosphorylation.

Tomar D, Jaña F, Dong Z, Quinn WJ 3rd, Jadiya P, Breves SL, Daw CC, Srikantan S, Shanmughapriya S, Nemani N, Carvalho E, Tripathi A, Worth AM, Zhang X, Razmpour R, Seelam A, Rhode S, Mehta AV, Murray M, Slade D, Ramirez SH, Mishra P, Gerhard GS, Caplan J, Norton L, Sharma K, Rajan S, Balciunas D, Wijesinghe DS, Ahima RS, Baur JA, Madesh M.

Cell Rep. 2019 Mar 26;26(13):3709-3725.e7. doi: 10.1016/j.celrep.2019.02.107.

5.

A Selective and Cell-Permeable Mitochondrial Calcium Uniporter (MCU) Inhibitor Preserves Mitochondrial Bioenergetics after Hypoxia/Reoxygenation Injury.

Woods JJ, Nemani N, Shanmughapriya S, Kumar A, Zhang M, Nathan SR, Thomas M, Carvalho E, Ramachandran K, Srikantan S, Stathopulos PB, Wilson JJ, Madesh M.

ACS Cent Sci. 2019 Jan 23;5(1):153-166. doi: 10.1021/acscentsci.8b00773. Epub 2019 Jan 4.

6.

FOXD1-dependent MICU1 expression regulates mitochondrial activity and cell differentiation.

Shanmughapriya S, Tomar D, Dong Z, Slovik KJ, Nemani N, Natarajaseenivasan K, Carvalho E, Lu C, Corrigan K, Garikipati VNS, Ibetti J, Rajan S, Barrero C, Chuprun K, Kishore R, Merali S, Tian Y, Yang W, Madesh M.

Nat Commun. 2018 Aug 29;9(1):3449. doi: 10.1038/s41467-018-05856-4.

7.

Molecular regulation of MCU: Implications in physiology and disease.

Nemani N, Shanmughapriya S, Madesh M.

Cell Calcium. 2018 Sep;74:86-93. doi: 10.1016/j.ceca.2018.06.006. Epub 2018 Jun 27. Review.

8.

MIRO-1 Determines Mitochondrial Shape Transition upon GPCR Activation and Ca2+ Stress.

Nemani N, Carvalho E, Tomar D, Dong Z, Ketschek A, Breves SL, Jaña F, Worth AM, Heffler J, Palaniappan P, Tripathi A, Subbiah R, Riitano MF, Seelam A, Manfred T, Itoh K, Meng S, Sesaki H, Craigen WJ, Rajan S, Shanmughapriya S, Caplan J, Prosser BL, Gill DL, Stathopulos PB, Gallo G, Chan DC, Mishra P, Madesh M.

Cell Rep. 2018 Apr 24;23(4):1005-1019. doi: 10.1016/j.celrep.2018.03.098.

9.

Mitochondrial Ca2+ Uniporter Is a Mitochondrial Luminal Redox Sensor that Augments MCU Channel Activity.

Dong Z, Shanmughapriya S, Tomar D, Siddiqui N, Lynch S, Nemani N, Breves SL, Zhang X, Tripathi A, Palaniappan P, Riitano MF, Worth AM, Seelam A, Carvalho E, Subbiah R, Jaña F, Soboloff J, Peng Y, Cheung JY, Joseph SK, Caplan J, Rajan S, Stathopulos PB, Madesh M.

Mol Cell. 2017 Mar 16;65(6):1014-1028.e7. doi: 10.1016/j.molcel.2017.01.032. Epub 2017 Mar 2.

10.

MCUR1 Is a Scaffold Factor for the MCU Complex Function and Promotes Mitochondrial Bioenergetics.

Tomar D, Dong Z, Shanmughapriya S, Koch DA, Thomas T, Hoffman NE, Timbalia SA, Goldman SJ, Breves SL, Corbally DP, Nemani N, Fairweather JP, Cutri AR, Zhang X, Song J, Jaña F, Huang J, Barrero C, Rabinowitz JE, Luongo TS, Schumacher SM, Rockman ME, Dietrich A, Merali S, Caplan J, Stathopulos P, Ahima RS, Cheung JY, Houser SR, Koch WJ, Patel V, Gohil VM, Elrod JW, Rajan S, Madesh M.

Cell Rep. 2016 May 24;15(8):1673-85. doi: 10.1016/j.celrep.2016.04.050. Epub 2016 May 12.

11.

Regulation of Sclerostin Expression in Multiple Myeloma by Dkk-1: A Potential Therapeutic Strategy for Myeloma Bone Disease.

Eda H, Santo L, Wein MN, Hu DZ, Cirstea DD, Nemani N, Tai YT, Raines SE, Kuhstoss SA, Munshi NC, Kronenberg HM, Raje NS.

J Bone Miner Res. 2016 Jun;31(6):1225-34. doi: 10.1002/jbmr.2789. Epub 2016 Feb 19.

12.

SPG7 Is an Essential and Conserved Component of the Mitochondrial Permeability Transition Pore.

Shanmughapriya S, Rajan S, Hoffman NE, Higgins AM, Tomar D, Nemani N, Hines KJ, Smith DJ, Eguchi A, Vallem S, Shaikh F, Cheung M, Leonard NJ, Stolakis RS, Wolfers MP, Ibetti J, Chuprun JK, Jog NR, Houser SR, Koch WJ, Elrod JW, Madesh M.

Mol Cell. 2015 Oct 1;60(1):47-62. doi: 10.1016/j.molcel.2015.08.009. Epub 2015 Sep 17.

13.

Ricolinostat (ACY-1215) induced inhibition of aggresome formation accelerates carfilzomib-induced multiple myeloma cell death.

Mishima Y, Santo L, Eda H, Cirstea D, Nemani N, Yee AJ, O'Donnell E, Selig MK, Quayle SN, Arastu-Kapur S, Kirk C, Boise LH, Jones SS, Raje N.

Br J Haematol. 2015 May;169(3):423-34. doi: 10.1111/bjh.13315. Epub 2015 Feb 23.

PMID:
25709080
14.

Role of decorin in multiple myeloma (MM) bone marrow microenvironment.

Nemani N, Santo L, Eda H, Cirstea D, Mishima Y, Patel C, O'Donnell E, Yee A, Raje N.

J Bone Miner Res. 2015 Mar;30(3):465-70. doi: 10.1002/jbmr.2371.

15.

Delineating the mTOR kinase pathway using a dual TORC1/2 inhibitor, AZD8055, in multiple myeloma.

Cirstea D, Santo L, Hideshima T, Eda H, Mishima Y, Nemani N, Mahindra A, Yee A, Gorgun G, Hu Y, Ohguchi H, Suzuki R, Cottini F, Guichard SM, Anderson KC, Raje N.

Mol Cancer Ther. 2014 Nov;13(11):2489-500. doi: 10.1158/1535-7163.MCT-14-0147. Epub 2014 Aug 29.

16.

Biomarkers of bone remodeling in multiple myeloma patients to tailor bisphosphonate therapy.

Patel CG, Yee AJ, Scullen TA, Nemani N, Santo L, Richardson PG, Laubach JP, Ghobrial IM, Schlossman RL, Munshi NC, Anderson KC, Raje NS.

Clin Cancer Res. 2014 Aug 1;20(15):3955-61. doi: 10.1158/1078-0432.CCR-14-0434. Epub 2014 Jun 23.

17.

A novel Bruton's tyrosine kinase inhibitor CC-292 in combination with the proteasome inhibitor carfilzomib impacts the bone microenvironment in a multiple myeloma model with resultant antimyeloma activity.

Eda H, Santo L, Cirstea DD, Yee AJ, Scullen TA, Nemani N, Mishima Y, Waterman PR, Arastu-Kapur S, Evans E, Singh J, Kirk CJ, Westlin WF, Raje NS.

Leukemia. 2014 Sep;28(9):1892-901. doi: 10.1038/leu.2014.69. Epub 2014 Feb 12.

PMID:
24518207
18.

Moyamoya disease: a case of vanishing cerebral vessels.

Thanavaro JL, Nemani N, Price HI.

J Am Assoc Nurse Pract. 2013 Apr;25(4):173-9. doi: 10.1111/j.1745-7599.2012.00782.x. Epub 2012 Sep 24.

PMID:
24218234
19.

Small-molecule multi-targeted kinase inhibitor RGB-286638 triggers P53-dependent and -independent anti-multiple myeloma activity through inhibition of transcriptional CDKs.

Cirstea D, Hideshima T, Santo L, Eda H, Mishima Y, Nemani N, Hu Y, Mimura N, Cottini F, Gorgun G, Ohguchi H, Suzuki R, Loferer H, Munshi NC, Anderson KC, Raje N.

Leukemia. 2013 Dec;27(12):2366-75. doi: 10.1038/leu.2013.194. Epub 2013 Jun 28.

20.

Lenalidomide in combination with an activin A-neutralizing antibody: preclinical rationale for a novel anti-myeloma strategy.

Scullen T, Santo L, Vallet S, Fulciniti M, Eda H, Cirstea D, Patel K, Nemani N, Yee A, Mahindra A, Raje N.

Leukemia. 2013 Aug;27(8):1715-21. doi: 10.1038/leu.2013.50. Epub 2013 Feb 18.

PMID:
23417027
21.

Distinctive clinical, radiographic, and functional characteristics of patients with sarcoidosis-related pulmonary hypertension.

Sulica R, Teirstein AS, Kakarla S, Nemani N, Behnegar A, Padilla ML.

Chest. 2005 Sep;128(3):1483-9.

PMID:
16162747

Supplemental Content

Loading ...
Support Center